Few smartphone product lines are as iconic as the Samsung Galaxy Note series. This series boldly went where few phones have before. Between the bleeding-edge tech, a focus on design, and a USP ...

As Stelara biosimilars gradually make their way on to the U.S. market, Johnson & Johnson has accused one early adopter—Samsung Bioepis—of violating the settlement that paved the way for the ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar. Johnson & Johnson on Monday sued Samsung ...

Johnson & Johnson sued Samsung Bioepis on Monday over that company’s moves to launch an additional biosimilar to J&J’s Stelara with a private label. The complaint and request for a preliminary ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...